logo
Plus   Neg
Share
Email

Pool Raises FY19 Earnings Outlook - Quick Facts

While reporting financial results for the first quarter, Pool Corp. (POOL) on Thursday raised its earnings guidance for the full-year 2019 as a result of the $0.04 per share additional tax benefit realized from ASU 2016-09 in the first quarter.

For fiscal 2019, the company now projects earnings in a range of $6.09 to $6.39 per share, up from the prior guidance range of $6.05 to $6.35 per share, which included an estimated $0.18 favorable impact from ASU 2016-09.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $6.23 per share for the year. Analysts' estimates typically exclude special items.

"Looking forward to the second quarter, we're excited about the many opportunities to continue to provide exceptional service to our customers as we head into the heart of the swimming pool season," said Peter Arvan, President and CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Just Egg, a plant-based egg alternative, will be available in 2,100 stores owned by grocery chain Kroger Co. later this month. The product launch comes as plant-based meat and egg alternatives gain traction in the country. Just Egg, a product of California-based food technology company Just Inc., will be available at Kroger-owned stores, including Kroger, Fred Meyer and Ralphs. Boeing has delivered the first 787-10 Dreamliner to Vietnam Airlines, the flag carrier of Vietnam, as part of the eight 787-10 Dreamliner airplanes to be delivered on lease through Air Lease. Vietnam Airlines said the 787-10 Dreamliner, claimed by Boeing to be the most fuel-efficient twin-aisle airplane in the industry, will help it raise the customer experience on the Hanoi to Ho Chi Minh route. The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria.
Follow RTT